Enhanced Virtual Trip platform goes live with improved user experience and first selection of PS2025 session videosConference ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the best get rich quick stocks to buy now. ARK Invest’s ETFs, led by Cathie Wood, ...

Market reaction to recent readouts from Compass Pathways and Beckley Psytech/atai in treatment-resistant depression speaks to ...

A single administration of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS 1 with a mean difference of -3.6 ...

LONDON & NEW YORK, June 23, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful ...

Research on synthetic psychedelics progresses, and there's hope to prove psilocybin safe and effective in intractable ...

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression ...

The COMP360 program aims to evaluate the safety and efficacy of COMP360 psilocybin, a synthetic, proprietary formulation of psilocybin under investigation for difficult-to-treat mental health ...

Compass Pathways plc (NASDAQ: CMPS) announced Monday that its Phase 3 COMP005 trial for COMP360, a synthetic formulation of psilocybin, met its primary endpoint in patients with treatment ...